McGuireWoods advised Revelstoke Capital Partners, a healthcare-focused private equity firm, in its recapitalization of AOM Infusion.
AOM Infusion — a specialty infusion provider focused on chronic therapy management — provides patients with intravenous immunoglobulin, biologics and other therapies, addressing more than 80 chronic conditions, with long-term treatment administered by skilled infusion nurses. The company also provides support services, including skilled infusion nursing administration, pharmacy services, referral management, insurance verification and patient education and training.
The significant investment was the ninth from Revelstoke Capital Partners Fund III.
Partner Tom Zahn led McGuireWoods’ deal team, which included partners Richard Massony, Holly Buckley, Amanda Roenius, Jennifer Shanley, Gretchen Townshend and Kevin Madagan, and associates Erin Lee, Joe Luzadder and Jennifer Murray.
“We value our longstanding relationship with Revelstoke and were pleased to assist our client in this important investment,” Zahn said. “This is another example of McGuireWoods’ unrivaled capabilities in healthcare private equity transactions.”
McGuireWoods is a dominant player in private equity deals involving physician practices, hospitals, outpatient and urgent-care providers, pharmacies, medical device manufacturers and distributors, and other healthcare services. The firm will host its 21st annual Healthcare Private Equity and Finance Conference May 14-15, 2025, in Chicago. The conference is one of the largest private equity events in the U.S. healthcare market.